Page 112 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Table 10. Protocols that did not report information on triggers for intervention in chronological order of starting enrollment year

Center, Term Age PSA Gleason # biopsy cores /% cores Imaging Stage Behavioral indication (other than
Country used (yr) (ng/mL) score patients’ choice or preference)
[Pubmed ID]
Enrollment
years
Kagawa EM;WW – “elevated ≤6 1-2 positive cores per 6 sextant – – –
Medical Univ., PSA” cores; ≤50% involvement of any
Japan 153 positive core
[10765093]
1990-1998
Kitasato Univ. WW – – – 6 sextant biopsy – “clinically –
Hospital, localized
Japan 154 prostate
[11851612] cancer”
1991-2000
Univ. of North EM – – – – – T1c –
Carolina, US 155
1991-1996
Princess AS – <10 <6 ≤3 positive biopsy cores (<50% – T1c-T2a –
Margaret of a core involved at initial
Hospital, diagnostic biopsy); fist-time
Canada 156 biopsies consisted of 6 cores
[21211899] before 2001 and 11 cores after
1995-2010 2001.
BCCA, WW – – – – – – Patient wish (37%), reduced life
Canada 157 expectancy due to medical problem
[9445192] (19%), physician recommendation
NR (42%); relative contraindication to
RT (2%)
a
Kansas City AS – <20 <6 <20% positive biopsy ≤ T2 –
VA, US 158
[21172105]
2004-2009
WW = watchful waiting; EM = expectant management; NR = not reported; DT = doubling time; mo = month(s); PAP = prostate acid phosphatase; PSA = prostate specific antigen;
TRUS = transrectal ultrasound; CT = computerized tomography; PSA = prostate-specific antigen; TNM = tumor-node-metastasis system; US = ultrasound; yr = year(s); BCCA =
British Columbia Cancer Agency
a
AS criteria were created explicitly for the analyses only, this is not a prospective AS cohort.

60